Global Meningitis Diagnostic Testing Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Meningitis Diagnostic Testing Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Meningitis Diagnostic Testing Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 – 2032

Global Meningitis Diagnostic Testing Market was valued at US $ 119.8 Million in 2023 and is expected to reach ~US $ 175 Million by 2032, growing at a CAGR of 3.8% from 2023 to 2032.

In the upcoming years, it is anticipated that the market for meningitis diagnostic testing would expand rapidly due to factors like rising disease awareness, better detection rates, and the creation of innovative treatment options. Throughout the projected period, beneficial measures to combat the disease with suitable diagnosis and treatment options are anticipated to promote market growth due to the rising frequency of meningitis.

During the projected period, the market is predicted to develop due to the anticipated rise in government participation in managing meningococcal disease outbreaks worldwide and the increasing need for quick diagnostic methods. For instance, the World Health Organisation (WHO) started work on a worldwide plan to battle meningitis by 2030 in November 2020, working with international partners involved in meningitis control and prevention. This project brought together hundreds of representatives from member states, partners, experts, stakeholders from the private sector, and civil society organisations through extensive and diverse consultations. It is projected that these measures would increase awareness of the significance of early meningitis diagnosis, which will accelerate market growth.

Additionally, aggressive alliances and joint ventures aimed at countering the danger posed by meningococcal infections are anticipated to fuel market expansion. One such is the collaboration between the Meningitis Research Foundation and the Global Meningococcal Initiative, which disseminates and funds top-notch research on effective methods for meningitis diagnosis and prevention across the globe. A number of diagnostics, including as PCR, ELISA, lateral flow assays, cultures, and standard laboratory tests like total protein and cerebrospinal fluid (CSF) testing, are frequently used to diagnose meningitis. The creation of innovative, cutting-edge, and precise tests will propel market expansion. Certain sophisticated diagnostics provide faster diagnosis times and increased sensitivity. For example, QIAGEN created the QIAstat-Dx Meningitis/Encephalitis Panel, a single rapid diagnostic test that can identify 15 microorganisms at once in an hour.

Global research initiatives to create quick and accurate diagnostic tools for meningococcal diseases are also driving the market's expansion. A five-year, USD 23.5 million EU grant was awarded to Imperial College London scientists in February 2020 with the goal of developing and commercialising a quick diagnostic test for meningitis throughout Europe. The unique gene signatures of this experimental test make it exceptional for diagnosing serious diseases. In addition, prominent industry participants are pursuing diverse organic and inorganic initiatives to attain a competitive edge and augment their market portion, thereby anticipated to provide substantial growth prospects in the market throughout the projected duration. For instance, QIAGEN announced improvements to its QIAstat-Dx syndromic testing technology in January 2022, which enables testing of several infections from a single sample in hospitals and laboratories. Additionally, this new test distinguishes between GI pathogens and meningitis infections.

“PCR assay segment, by diagnostic type, to be dominating market from 2023 to 2030.”

The segmentation analysis of the treatment type segment is as Latex Agglutination Tests, Lateral Flow Assay Tests, PCR Assay Tests, Elisa Tests, Culture Tests and Others. Based on test type, the PCR assay segment held a dominant market share in 2022. This was mostly caused by a number of things, such as the availability of a wide range of PCR test products and the high preference for PCR assays in meningitis detection because of their remarkable accuracy. PCR assays are also well-known for their increased sensitivity, which produces extremely accurate and dependable results and supports its use in meningitis testing. The use of PCR assays is also being fuelled by the commercial availability of numerous RT-PCR platforms that can provide findings for both single-target and multi-target detection tests in less than two hours. Furthermore, this market is predicted to see significant growth due to continuing technological developments in PCR assays that aim to improve diagnostic precision and reduce turnaround times. For example, bioMerieux SA's BIOFIRE FILMARRAY ME PANEL allows for quick and precise testing for common pathogens that cause different CNS diseases.

“Household segment, by end-user, to be fastest growing market from 2023 to 2030.”

The segmentation analysis of the end-user segment is as hospitals, diagnostic laboratories, ambulatory surgical centres, academic and research institutes and others. This market is likely to continue growing throughout the forecast period due in part to the large number of patients in hospital settings who require the best treatment possible. In addition, these hospitals guarantee better patient access because they are manned by trained medical personnel and have state-of-the-art diagnostic equipment. The growth is also expected to be driven by rising healthcare spending per capita. The World Bank reports that global spending on healthcare increased to 9.83% in 2019 from 9.7% in 2018. Over the course of the projection year, the severity of meningitis and its elevated hospitalisation rate are expected to drive further growth in this industry. In the next years, the diagnostic centres market is expected to rise at a very quick pace. This category is expanding due in large part to the rise in the prevalence of infectious diseases and the increasing use of high-tech gadgets for precise and accurate diagnostic results. In addition, a number of diagnostic centres that provide meningitis diagnostic tests, like UCSF Labs and ARUP Laboratories, are fuelling the sector's expansion over the projection period.

“North America to be largest region in Meningitis Diagnostic Testing Market.”

North American manufacturers are seeing chances to grow their businesses because to the growing demand for meningitis diagnostic therapy in the healthcare industry. There are many manufacturers and suppliers in North America, and the country's quick economic development has increased industrial production, which in turn has increased demand for meningitis diagnostic testing. Meningitis Diagnostic Testing market share in North America has grown due to a number of factors, including rising healthcare costs, an increase in research studies, technological advancements for treating metabolic diseases, and the opening of pharmaceutical and biotechnology companies throughout the region. It is anticipated that the region's need for meningitis diagnostic testing would increase as a result of cooperative research projects between major healthcare organisations and enterprises. The market is expanding in part because of continuous efforts to improve current treatment choices through new product development. The market in this region is expected to grow further as people become more aware of other treatment options, such as cysteine-depleting therapy for management purposes. The dominance of North America in the global market for meningitis diagnostic testing is highlighted by these considerations.

Meningitis Diagnostic Testing Competitive Landscape

The competitive landscape of the Meningitis Diagnostic Testing Market involves assessing the competitive landscape to understand the strengths, weaknesses, opportunities, and threats of the industry. Key industry players have recognized that the adoption of Meningitis Diagnostic Testing technology holds the potential for further growth. The growing desire among producers to optimize their production costs has spurred collaborative efforts among companies to scale up their production capacity. This strategic collaboration not only aims to increase revenue but also seeks to establish dominance in the market.

The Meningitis Diagnostic Testing Market is highly competitive, with numerous companies vying for market share. Prominent companies in the Meningitis Diagnostic Testing Market include:

Major Players:

Thermo Fisher Scientific, Inc.

Bio-Rad Laboratories, Inc.

Abbott

ELITechGroup

Seegene Inc.

Luminex Corporation

CERTEST BIOTEC

IMMY

Uniogen Oy

Recent Developments:

QIAGEN N.V. reported progress in commercialising their syndromic testing product, QIAstat-Dx, in January 2022. This innovation makes it possible for labs and medical facilities all around the world to screen for several infections with a single patient sample. It involves releasing a higher-throughput version with improved walk-away efficiency thanks to the ground-breaking QIAstat-Dx Smart Drawer, as well as adding new tests.

Abacus Diagnostics, a division of Uniogen, unveiled the GenomEra assay kit (HSV-1/2, VZV + EV Assay Kit), a novel quick PCR test, to the European market in July 2022. This innovative medical technique represents a major breakthrough in medical diagnostics by enabling the quick and accurate identification of the viruses causing viral meningitis and encephalitis.

.